Related Experiment Video
Updated: Aug 23, 2025
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
Nataliya P Buxbaum1, Gerard Socié2, Geoffrey R Hill3,4
1Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Insights
Chronic graft-versus-host disease (cGvHD) is a major complication after stem cell transplants. Recent research is paving the way for personalized therapies to improve patient outcomes.
Area of Science:
- Hematology
- Immunology
- Transplantation Medicine
Background:
- Chronic graft-versus-host disease (cGvHD) is a significant cause of mortality and morbidity following allogeneic hematopoietic stem cell transplantation.
- Despite advances, cGvHD treatment has historically been empirical, lacking patient-specific approaches.
- Individual patient variability in cGvHD manifestations suggests diverse underlying biological mechanisms.
Purpose of the Study:
- To review recent advancements in understanding cGvHD pathophysiology.
- To outline a strategy for developing personalized treatment approaches for cGvHD.
- To bridge the gap between basic research and clinical application in cGvHD therapy.
Main Methods:
- Review of current literature on cGvHD pathophysiology and treatment.
- Analysis of clinical observations regarding disease heterogeneity.
- Synthesis of bench and bedside research findings.
Main Results:
- Elucidation of complex pathophysiological pathways contributing to cGvHD.
- Identification of diverse biological underpinnings driving clinical variability.
- Emerging focus on personalized medicine strategies.
Conclusions:
- Personalized approaches are crucial for effective cGvHD management.
- Integrating recent knowledge is key to tailoring therapies.
- Future directions involve patient-specific treatment strategies for improved outcomes.
Abstract:
Chronic graft-versus-host disease (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of nonrelapse mortality and significant morbidity. Tremendous progress has been achieved in both the understanding of pathophysiology and the development of new therapies for cGvHD. Although our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized approaches to treatment. The intent of this article is to concisely review recent knowledge gained and formulate a path toward patient-specific cGvHD therapy.
More Related Videos
09:00High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...